Global Information
회사소개 | 문의 | 비교리스트

세계의 디지털 정량 흡입기 시장(2019-2023년)

Digital Dose Inhalers Market by Product and Geography - Global Forecast and Analysis 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 08월 상품 코드 910206
페이지 정보 영문 130 Pages
가격
US $ 2,500 ₩ 3,107,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,728,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,971,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,214,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 디지털 정량 흡입기 시장(2019-2023년) Digital Dose Inhalers Market by Product and Geography - Global Forecast and Analysis 2019-2023
발행일 : 2019년 08월 페이지 정보 : 영문 130 Pages

세계 디지털 정량 흡입기 시장은 만성 호흡기질환 유병률 증가, 유명 기업의 제품 발매 증가, 기술 진보 등이 성장 촉진요인이 되어 예측기간 중 약 13%의 연평균 복합 성장률(CAGR)로 확대될 전망입니다. 하지만, 디지털 정량 흡입기에 관련된 높은 비용, 인식 부족과 상호운용성 결여, 디지털 정량 흡입기의 한정적인 입수 가능성, 디지털 보안 문제가 예측기간 중 디지털 정량 흡입기 시장의 성장을 방해할 가능성이 있습니다.

세계의 디지털 정량 흡입기(Digital Dose Inhalers) 시장에 대해 조사 분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인과 과제, 시장 기회 분석, 주요 벤더 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 주요 요약

제2장 조사 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환산율

제3장 시장 상황

  • 시장 생태계
  • 시장의 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대체품의 위협
  • 경쟁사의 위협
  • 시장 현황

제6장 시장 세분화 : 제품별

  • 시장 세분화 : 제품별
  • 제품별 비교 : 시장 규모 및 예측(2018-2023년)
  • 정량 및 소프트 미스트 흡입기
  • 건조 분말 흡입기
  • 시장 기회 : 제품별

제7장 고객 상황

제8장 지역별 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제9장 의사결정 프레임워크

제10장 성장 촉진요인과 과제

  • 시장 성장 촉진요인
  • 시장의 과제

제11장 시장 동향

  • 인공지능(AI)의 고도 통합과 사물인터넷(IoT) 채용
  • 사업 전략
  • 인터넷 접속 증가와 스마트폰 디바이스 사용

제12장 벤더 상황

  • 개요
  • 파괴적 혁신
  • 경쟁 시나리오

제13장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health Inc.
  • Teva Pharmaceutical Industries Ltd.

제14장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제15장 TECHNAVIO에 대해

LSH 19.09.17

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global medical devices market
  • Exhibit 03: Segments of global medical devices market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Hospital admission rate for asthma and COPD in adults in 2015 per 100,000 population
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Metered dose and soft mist inhalers - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Metered dose and soft mist inhalers - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Dry powder inhalers - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Dry powder inhalers - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Percentage of population with self-reported COPD aged 15 and over in 2014 (Europe)
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: AstraZeneca Plc - Vendor overview
  • Exhibit 47: AstraZeneca Plc - Product segments
  • Exhibit 48: AstraZeneca Plc - Organizational developments
  • Exhibit 49: AstraZeneca Plc - Geographic focus
  • Exhibit 50: AstraZeneca Plc - Segment focus
  • Exhibit 51: AstraZeneca Plc - Key offerings
  • Exhibit 52: AstraZeneca Plc - Key customers
  • Exhibit 53: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 54: GlaxoSmithKline Plc - Business segments
  • Exhibit 55: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 56: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 57: GlaxoSmithKline Plc - Segment focus
  • Exhibit 58: GlaxoSmithKline Plc - Key offerings
  • Exhibit 59: GlaxoSmithKline Plc - Key customers
  • Exhibit 60: Novartis AG - Vendor overview
  • Exhibit 61: Novartis AG - Business segments
  • Exhibit 62: Novartis AG - Organizational developments
  • Exhibit 63: Novartis AG - Geographic focus
  • Exhibit 64: Novartis AG - Segment focus
  • Exhibit 65: Novartis AG - Key offerings
  • Exhibit 66: Novartis AG - Key customers
  • Exhibit 67: OPKO Health Inc. - Vendor overview
  • Exhibit 68: OPKO Health Inc. - Business segments
  • Exhibit 69: OPKO Health Inc. - Organizational developments
  • Exhibit 70: OPKO Health Inc. - Geographic focus
  • Exhibit 71: OPKO Health Inc. - Key offerings
  • Exhibit 72: OPKO Health Inc. - Key customers
  • Exhibit 73: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 74: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 75: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 76: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 77: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 78: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
  • Exhibit 80: Definition of market positioning of vendors

About this market

Technavio's digital dose inhalers market analysis considers sales from both metered-dose and soft mist inhalers and dry powder inhalers . Our analysis also considers the sales of digital dose inhalers in Asia. Europe, North America, and ROW. In 2018, the metered dose and soft mist inhalers segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as delivery of accurate dose during inhalation, cost-effectiveness will play a significant role in the metered-dose and soft mist inhalers segment to maintain its market position. Also, our global digital dose inhalers market report looks at factors such as increasing prevalence of chronic respiratory diseases, increasing product launches by prominent players, and technological advances. However, high costs associated with digital dose inhalers, lack of awareness and interoperability, and limited availability of digital dose inhalers and digital security issues may hamper the growth of the digital dose inhalers industry over the forecast period.

Overview

Technological advancements

Digital dose inhalers or smart inhalers are an advanced type of inhalers, which help to achieve an effective outcome for COPD and asthma. Pharmaceutical companies are developing smart mist inhalers that optimize and improve drug delivery in patients with COPD. Market vendors are increasingly integrating Bluetooth technology and digitalizing inhaler devices to minimize common errors by measuring patient inhalation, increase the drug delivery efficacy, reduce health care costs, improve medication adherence, and enhance patient outcome. Such benefits of technological advancements will lead to the expansion of the global digital dose inhalers market at a CAGR of almost 13% during the forecast period.

Rising integration of AI and the adoption of IoT

Digitalization has opened the doors for healthcare professionals to improve the treatment of asthma and COPD. AI technology uses algorithms and software to analyze complex medical data and minimizes the need for direct human input. Moreover, IoT based digital inhalers help customers to monitor their condition, understand the measurement of dosage, and prevent subsequent respiratory attacks. The sensors integrated digital dose inhaler systems help in minimizing emergency visits reducing risks and enhances patient outcome. This rise in the integration of AI and IoT is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global digital dose inhalers market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global digital dose inhalers market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading digital dose inhalers manufacturers, that include AstraZeneca Plc, GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Teva Pharmaceutical Industries Ltd.

Also, the digital dose inhalers market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Metered dose and soft mist inhalers - Market size and forecast 2018-2023
  • Dry powder inhalers - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Rising integration of AI and adoption of IoT
  • Business strategies
  • Growing internet connectivity and use of smartphone devices

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health Inc.
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Back to Top
전화 문의
F A Q